Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Oncology Pharma Inc (OTCMKTS: ONPH) stock price edged 8.82% despite the lack of news releases from the oncology company. The firm has not made any significant announcements for a long time now, leaving investors guessing its next move.
Therefore, we have to look at its portfolio companies for clues. To start with, Oncology Pharma’s portfolio companies include NanoSmart Pharmaceuticals, Sybleu Inc., Connect2Med and Regen.
The most visible business is NanoSmart Pharmaceuticals, which has developed a novel drug delivery system targeting multiple types of cancers and other disorders.
Oncology Pharma has a worldwide licensing agreement with Sybleu Inc. for its Cancer therapy administered via intratumoral injection of a chemotherapeutic agent combined with a bioactive immunostimulatory agent.
The chemotherapeutic agent used is AQ4 & AQ4N, while the bioactive agent is made from TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.
Neither of these two businesses has announced any new projects or partnerships that could generate revenues for Oncology Pharma.
The other two business units are Connect2Med, a social engagement and retention platform for clinical trials. Finally, Regen is a small molecule checkpoint NR2F6, an antigen-specific mRNA cellular cancer vaccine.
Today rally in Oncology Pharma stock is a good sign since the stock has been in a downtrend since June this year and is long overdue for a relief rally. However, we might need a solid fundamental release to drive the stock price higher.
*This is not investment advice.
Oncology Pharma stock price.
Oncology Pharma shares edged 8.82% higher to trade at $8.41, rising from Tuesday’s closing price of $7.74.
Tech stocks offer some of the best growth potential, but time and time again, traders and investors ask us “what are the best tech stocks to buy?” You've probably seen shares of companies such as Amazon and Netflix achieve monumental rises in the past few years, but there are still several tech stocks with room for significant gains. Here is our analysts view on the best tech stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .